HCV / Hepatitis

Despite hepatitis C (HCV) incidence rates increasing, adequate screening for the virus continues to be a pressing challenge for public health officials.

A study reported at IDWeek looked at this population and found gaps in testing.

The companies' initial focus will be around Assembly’s established areas of development including hepatitis B and D, as well as herpesviruses.

There is a lack of information and teaching going on with this significant, but "silent" organ.

With its Cherokee Nation Hepatitis C Elimination program, they have worked diligently to increase screening and get people into the continuum of care.

A study highlights that viral infections can accelerate the progression of NAFLD to more severe conditions like non-alcoholic steatohepatitis (NASH) and fibrosis, emphasizing the importance of recognizing these complex relationships.

This action paves the way for this long-acting injectable to be used in several countries on the European continent.

The expanded indication to those with severe hepatic impairment has already been granted in the US and EU.

Review of hepatitis D virus describes “unique” biologic characteristics and “ominous” medical effect, but constrained as HBV treatments affect HDV life cycle.

Vaccitech is using a novel approach to address the virus and create a functional cure.

Long-term follow-up of DAA treatment of HCV infection after liver transplant shows persistent improvement in hepatic function, fibrosis, and survival rate.

There are a number of innovative, virus-targeting agents in development to treat hepatitis C (HCV) and prevent the virus.

Hurricane season is accompanied by an uptick in infectious diseases associated with environmental and water exposures.

A study found variations in treatment initiation, especially showing differences within certain populations, ages, and those with a background of injection drug use.

In this week's news: A CDC committee recommends the updated COVID-19 vaccines; the cost of misinformation during the pandemic; and India is dealing with a Nipah virus outbreak.

A global review demonstrates the potential depth of the impact of the COVID-19 pandemic on ongoing immunization delay and skepticism.

Several trial participants experienced concerning hepatobiliary events.

The federal agency’s reports shows decreases in both hepatitis A and B, but hepatitis C saw a significant increase during 2021. However, the investigators note the pandemic may have impacted statistics and progress towards goals.

Biotech company is developing a product for a potential functional cure of the virus.

The formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) is a once-daily treatment for children living with HIV and meant to reduce pill burden.

Investigators found that while general hospitalizations decreased in 2020, hospitalizations due to alcohol-associated hepatitis increased by 16%.

Associated with excessive alcohol use, cirrhosis is one condition that can affect the pediatric population in the absence of alcohol.

With low vaccine utilization rates, finding educational resources to inform the public and increase attention to this preventative measure is needed to increase vaccinations.

Unique challenges can affect the success of the shift from pediatric to adult care settings.

Study compares efficiency of expanding HCV screening for all persons with HIV to programs focused on those at higher risk of HCV.